From: Cross-species virus transmission and its pandemic potential
Name | Type | Efficacy (%) | Dosage | Storage | Country/origin |
---|---|---|---|---|---|
Covaxin | Inactivated virus vaccine | 81 | 2 doses with a gap of 28 days in between | + 2–8 °C | Bharat Biotech (India) |
BBIBP—CorV | Inactivated virus vaccine | 72–86 | 2 doses with a gap of 21 days in between | + 2–8 °C | Sinopharm (China) |
CoronaVac | Inactivated virus vaccine | 50.7–83.7 | 2 doses with a gap of 14 days in between | + 2–8 °C | SinoVac (China) |
JNJ-78436735 | Viral vector vaccine | 72 | 1 dose | + 2–8 °C for short-term storage and − 20 °C for long term storage | Johnson and Johnson (USA) |
Sputnik V | Viral vector vaccine | 91 | 2 doses with a gap of 21 days in between | + 2–8 °C for short-term storage and − 20 °C for long term storage | Gamaleya (Russia) |
Novavax | Virus-like particle vaccine | 96 | 2 doses with a gap of 21 days in between | + 2–8 °C for short-term storage and − 20 °C for long term storage | (USA) |
Covishield | Viral vector vaccine | 70–82 | 2 doses with a gap of upto 12 weeks in between | + 2–8 °C | Oxford/Astrazneca (UK and Sweden) |
BioNTech/Pfizer | Encapsulated mRNA vaccine | 96 | 2 doses with a gap of 21 days in between | + 2–8 °C for 5 days and − 70 °C for longer duration | (USA and Germany) |
Moderna | Encapsulated mRNA vaccine | 94.1 | 2 doses with a gap of 28 days in between | + 2–8 °C for short-term storage and − 20 °C for long term storage | USA |